Lead Product(s): DiNA-001
Therapeutic Area: Genetic Disease
Highest Development Status: IND Enabling Product Type: Gene therapy
Partner/Sponsor/Collaborator: BioMarin Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 03, 2020
The license initially covers DiNAQOR's lead program, DiNA-001 for MYBPC3 hypertrophic cardiomyopathy. Additionally, the companies will collaborate on several of DiNAQOR's other pipeline programs.